Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism
VOQUEZNA's FDA exclusivity through 2032 and superior efficacy in GERD and H. pylori create a strong competitive moat in a $3.2B+ market. Rapid commercial uptake, robust DTC marketing, and >80% insurance coverage have driven $55M+ first-year sales and 390,000+ prescriptions. Discounted cash flow analysis supports a $14/share price target (43% upside potential), with near-term catalysts in sales growth, EU partnerships, and pipeline expansion.
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
I'm bullish on Phathom Pharmaceuticals, Inc. after the FDA granted 10-year exclusivity to their flagship GI drug, Voquezna, giving them near-monopoly status. For those who don't know, this is a big deal because the FDA doesn't grant exclusivity rights often. Voquezna's prescription growth is surging, now with 390,000 fills and 127,000 in Q1 2025 alone, which is driving strong revenue momentum.
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
The consensus price target hints at a 107.4% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals (PHAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.42 per share a year ago.
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Joseph Stringer - Needham Annabel Samimy - Stifel Kristen Kluska - Cantor Fitzgerald Paul Choi - Goldman Sachs Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.80 per share a year ago.
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround
Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know
Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial & Business Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Paul Choi - Goldman Sachs Joseph Stringer - Needham & Company Yatin Suneja - Guggenheim Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to the Phathom Pharmaceuticals Third Quarter 2024 Earnings Results Call.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to loss of $0.76 per share a year ago.
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President and CEO Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - Needham & Company Yatin Suneja - Guggenheim Paul Choi - Goldman Sachs Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to Phathom Pharmaceuticals Second Quarter 2024 Earnings Results Call.
